FDA Recognizes Allogeneic CAR T Therapy for Lymphomas


CB-010 most recently demonstrated a 100% complete response rate in data presented at the EHA 2022 congress.

The FDA has granted fast track designation to Caribou Biosciences’ chimeric antigen receptor (CAR) T-cell therapy CB-010 for treating relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) and regenerative medicine advanced therapy designationfor treating R/R large B cell lymphoma (LBCL).1

“RMAT and Fast Track designations for CB-010 are important recognitions of the significant unmet patient need for an off-the-shelf cell therapy in the treatment of aggressive B-NHL,” Rachel Haurwitz, PhD, president and chief executive officer, Caribou Biosciences, said in a statement.1 “Through genome editing with our precision CRISPR chRDNA genome-editing technology, CB-010 has been designed with a PD-1 knockout strategy to improve the persistence of antitumor activity by limiting premature CAR-T cell exhaustion. In our ANTLER Phase 1 trial, 3 of 6 patients treated with CB-010 at dose level 1 maintained a durable complete response at 6 months. We are encouraged that CB-010 has demonstrated early potential as an off-the-shelf cell therapy that may meaningfully rival autologous cell therapies.”

CB-010 is being evaluated in the phase 1 ANTLER trial (NCT04637763) in patients with diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and primary mediastinal large B-cell lymphoma.2 Data most recently presented from the ANTLER trial at the European Hematology Association (EHA) 2022 Congress in June showed that all 6 patients dosed with 40x106 CB-010 cells in cohort 1 had complete responses (CRs) which continued up to 6 months in 2 of 5 patients that reached that follow-up. Altogether, 3 patients have a continuing response. The longest follow-up is 12 months in the first patient withB-NHL who has a continuing CR.

READ MORE: Allogeneic CAR T Yields 15-Month CR in Follicular Lymphoma

CB-010 had a manageable safety profile. All study participants experienced treatment-emergent adverse events (AEs) and 4 participants experienced treatment-related AEs of grade 3 or higher including neutropenia, thrombocytopenia, and white blood cell count decrease. Two patients also developed low grade cytokine release syndrome, 1 developed grade 3 immune effector cell-associated neurotoxicity syndrome, and 2 patients developed grade 2 and 3 infections. No graft-versus-host disease has been observed.

“We believe the 100% complete response achieved in the ANTLER CB-010 trial is unparalleled for a single, starting dose of cell therapy and represents an important step toward showing the potential of our chRDNA genome-editing platform and pipeline of allogeneic cell therapies,” Haurwitz said in a previous statement.“As the first allogeneic anti-CD19 CAR-T cell therapy in the clinic with a PD-1 knockout, CB-010 is designed to have sustained antitumor activity by limiting premature CAR-T cell exhaustion in patients with r/r B-NHL. As we enroll patients in cohort 2 at dose level 2 of the ANTLER trial, we are grateful for the patients, caregivers, and investigators who have participated in this clinical trial. We continue to advance CB-010, as our goal is to develop an allogeneic cell therapy that may meaningfully rival autologous cell therapies and extend the potential reach of off-the-shelf treatments for patients.”

CB-010 is an allogeneic anti-CD19 CAR T-cell therapy, designed to improve the persistence of antitumor activity and limit CAR T-cell exhaustion.1 The therapy is genome-edited by use of Caribou’s next-generation CRISPRplatform that uses Cas9 CRISPR hybrid RNA-DNA to insert a CD19-specific CAR into the TRAC gene and knock out PD-1.

1. Caribou Biosciences announces the FDA granted regenerative medicine advanced therapy (RMAT) and fast track designations to CB-010, an allogeneic anti-CD19 CAR-T cell therapy. News release. Caribou Biosciences. November 29, 2022. https://www.globenewswire.com/news-release/2022/11/29/2564105/0/en/Caribou-Biosciences-Announces-the-FDA-Granted-Regenerative-Medicine-Advanced-Therapy-RMAT-and-Fast-Track-Designations-to-CB-010-an-Allogeneic-Anti-CD19-CAR-T-Cell-Therapy.html
2. Nastoupil LJ, O’Brien S, Holmes HE, et al. First-in-human trial of CB-010, a CRISPR-edited allogeneic anti-cd19 CAR T-cell therapy with a pd-1 knock out, in patients with relapsed or refractory b cell non-Hodgkin lymphoma (Antler study). Presented at: EHA 2022 Congress, June 9-12, Vienna, Austria and virtually. Abstract #3103
Related Videos
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi
Mark Walters, MD
Manali Kamdar, MD, on Bringing Liso-Cel to Earlier Lines of Treatment
Omid Hamid, MD, on Assessing TIL Combination Therapies, Expanding Past Melanoma
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
David Suhy, PhD, the cofounder and chief scientific officer of Earli
© 2024 MJH Life Sciences

All rights reserved.